OTIC Otonomy Inc.

2
-0.01  -1%
Previous Close 2.01
Open 2.02
Price To Book 0.68
Market Cap 61260250
Shares 30,630,125
Volume 20,183
Short Ratio
Av. Daily Volume 161,131

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated 3Q 2019 with data due 2H 2020.
OTO-413
Hidden hearing loss
Phase 3 data released August 30 failed to meet primary and key secondary endpoints.
OTO-104 AVERTS-1
Meniere's disease
Phase 1/2 trial to be initiated 2Q 2019 with data due 1H 2020.
OTO-313
Tinnitus
Additional Phase 3 trial data due 1H 2020.
OTIVIDEX
Ménière's disease
Phase 2 trial completed October 2016. Phase 3 trial planned.
OTIPRIO
Pediatric patients with acute otitis media with tympanostomy tubes (AOMT)
Phase 2 trial initiation announced January 19, 2017.
OTO-104
Prevention of hearing loss in cancer patients undergoing chemotherapy
Approved December 11, 2015
OTIPRIO (ciprofloxacin otic suspension)
Ear Tube Placement Surgery
Approval announced March 2, 2018.
OTIPRIO
Acute otitis externa